Prescriber's Corner

Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma

Gwen Hua,(1) PharmD, Daniel Carlson,(2) DO, and Jacqueline R. Starr,(1) PharmD, BCOP

From (1)Geisinger Enterprise Pharmacy, Danville, Pennsylvania; (2)Geisinger Cancer Institute, Danville, Pennsylvania

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Gwen Hua, PharmD, 100 N Academy Ave, Danville, PA 17822 E-mail: ghua@geisinger.edu


J Adv Pract Oncol 2022;13(7):717–723 | https://doi.org/10.6004/jadpro.2022.13.7.8 | © 2022 Harborside™


  

ABSTRACT

Uveal melanoma is the most common intraocular cancer in adults. Metastatic uveal melanoma has a poor prognosis. Tebentafusp-tebn is the first drug in the new immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC) class of T cell–directed therapy. Tebentafusp-tebn has been shown in a randomized phase III clinical trial to lead to improved overall survival and progression-free survival when compared with single-agent pembrolizumab, ipilimumab, or dacarbazine in previously untreated human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma patients. Tebentafusp-tebn is now approved by the US Food and Drug Administration in HLA-A*02:01-positive uveal melanoma patients as first-line therapy in the metastatic setting. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.